KLK3 and prostate cancer: Clinically, abiraterone acetate (oral; four 250 mg tablets once daily with oral prednisone 5 mg twice daily) is shown to significantly improve median overall survival compared to placebo in metastatic CRPC (mCRPC; histologically confirmed prostate cancer, N1/M1, more than two [or three in other studies] consecutive rises in PSA levels over 25 % above nadir value following surgical or chemical ADT for at least 1 week) patients with or without previous chemotherapy [94–97].